Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 28, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 500,000 ordinary shares of 25 pence each.
- Purchase Price: 1,432.05 pence per share.
- Treasury Shares Held: 117,788,000 shares (post-transaction).
- Shares in Issue: 5,829,986,237 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 25, 2005. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 500,000 share repurchase based on the stated price of 1,432.05 pence.
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the May 25, 2005 Annual General Meeting minutes to understand the full scope of the share buyback authorization.